enVVeno Medical (NVNO)
NASDAQ:NVNO
Want to see NVNO full AI Analyst Report?
NVNO Stock Chart & Stats
$0.36
-$0.06(-1.92%)
At close: 4:00 PM EST
$0.36
-$0.06(-1.92%)
Day’s Range― - ―
52-Week Range$8.67 - $196.70
Previous CloseN/A
Volume33.14K
Average Volume (3M)589.93K
Market Cap
$6.68M
Enterprise Value-$1.81M
Total Cash (Recent Filing)$24.93M
Total Debt (Recent Filing)$603.00K
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1147.01
Shares Outstanding667,669
10 Day Avg. Volume395,892
30 Day Avg. Volume589,933
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.25
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap-0.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.68
Enterprise Value/Ebitda0.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-35
Revenue Forecast (FY)$7.00M
Bulls Say, Bears Say
Bulls Say
Regulatory Milestone (IDE Approval)IDE approval creates a durable regulatory pathway to generate pivotal clinical data in the U.S. The two-stage TAVVE trial (10-patient safety cohort then 220-patient randomized phase) de-risks long-term commercialization prospects and enables a potential PMA route for an unmet-market therapy.
Low Financial LeverageVery low debt provides structural financial flexibility for a pre-revenue device developer, reducing interest burden and covenant risk. This allows management to prioritize trial execution and R&D without immediate debt-servicing constraints, supporting multi-quarter development timelines.
Near-term Cash RunwayReported cash and investments providing runway into Q3 2027 materially supports completing the early stages of the TAVVE pivotal program and related operational activities, reducing near-term refinancing pressure and allowing focus on enrollment, manufacturing scale-up, and regulatory milestones.
Bears Say
Pre-revenue StatusBeing pre-revenue is a foundational limitation: the business lacks recurring commercial cash flows and remains fully dependent on successful trials and future approvals to monetize the technology. This structural dependency extends funding risk and execution uncertainty over multiple quarters.
Sustained Negative Cash FlowConsistent negative operating and free cash flow creates an ongoing need for external financing; this persistent cash burn can force dilution or constrain trial pace and commercialization investments unless revenues or non-dilutive funding emerge, a structural financing risk for a clinical-stage device maker.
Eroding Equity & Poor ReturnsDeclining equity and negative returns indicate the balance sheet is being consumed by operating losses. This deterioration weakens resilience to setbacks, reduces strategic optionality, and may impair the company’s ability to obtain favorable partnership or financing terms over the medium term.
enVVeno Medical News
NVNO FAQ
What was enVVeno Medical’s price range in the past 12 months?
enVVeno Medical lowest stock price was $8.67 and its highest was $196.70 in the past 12 months.
What is enVVeno Medical’s market cap?
enVVeno Medical’s market cap is $6.68M.
When is enVVeno Medical’s upcoming earnings report date?
enVVeno Medical’s upcoming earnings report date is Jul 30, 2026 which is in 45 days.
How were enVVeno Medical’s earnings last quarter?
enVVeno Medical released its earnings results on May 07, 2026. The company reported -$5.885 earnings per share for the quarter, missing the consensus estimate of N/A by -$5.885.
Is enVVeno Medical overvalued?
According to Wall Street analysts enVVeno Medical’s price is currently Overvalued.
Does enVVeno Medical pay dividends?
enVVeno Medical does not currently pay dividends.
What is enVVeno Medical’s EPS estimate?
enVVeno Medical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does enVVeno Medical have?
enVVeno Medical has 667,669 shares outstanding.
What happened to enVVeno Medical’s price movement after its last earnings report?
enVVeno Medical reported an EPS of -$5.885 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.49%.
Which hedge fund is a major shareholder of enVVeno Medical?
Currently, no hedge funds are holding shares in NVNO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
enVVeno Medical
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
Technical Analysis
Ownership Overview
9.46% Insiders
1.91% Mutual Funds
10.77% Other Institutional Investors
76.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---